Press release
China Market Analysis of PARP Inhibitors: Growth Opportunities
Global PARP Inhibitors Market: IntroductionA PARP (poly ADP-ribose polymerase) inhibitor is a substance that blocks PARP enzyme in the cell. DNA damage occurs during cancer. Blocking of PARP helps the cancer cells in repairing their damaged part of DNA.
Read Report Overview - https://www.transparencymarketresearch.com/parp-inhibitors-market.html
Global PARP Inhibitors Market: Competition Landscape
Key players operating in the global PARP inhibitors market are AstraZeneca, Tesaro, AbbVie Inc., Medivation, and Clovis Oncology. The global market is highly consolidated, with the presence of a small number of manufacturers. Increase in strategic collaborations and new product launches are expected to drive the global PARP inhibitors market during the forecast period.
AstraZeneca
AstraZeneca is a biopharmaceutical company engaged in the discovery, manufacture, distribution, and commercialization of biopharmaceutical products. The company is a leading player in the global pharmaceutical sector. It offers various services and products in therapeutic areas such as cardiovascular and metabolic diseases; oncology; and respiratory, inflammation, and autoimmunity (RIA). Additionally, the company provides products useful in the treatment of infections, neurologic disorders, and gastrointestinal diseases. With a high focus on research and development for certain specific aspects of neurodegenerative diseases, analgesia, and psychiatry, AstraZeneca continues to collaborate with other innovative partners across industry and academia. The areas of cognitive disorders, chronic pain, and other central nervous system disorders still experience significant unmet medical needs.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=71682
AbbVie Inc.
AbbVie, Inc. develops and distributes pharmaceutical products worldwide. The company offers pharmaceutical products for use in testosterone replacement therapy and the treatment of hypothyroidism and autoimmune diseases. It distributes products directly to wholesalers, government agencies, distributors, health care facilities, and specialty pharmacies worldwide. HUMIRA, a biologic therapy for the treatment of autoimmune diseases, is the company’s blockbuster drug. It accounted for around 63% share of the company’s sales revenues in 2014. The company sells its products in more than 170 countries across the globe.
Global PARP Inhibitors Market: Dynamics
The global PARP inhibitors market is primarily driven by increase in the rates of incidence and prevalence of cancer. In addition, increase in the adoption of PARP inhibitor drugs, growth of geriatric population, and advancements in the global health care sector are expected to boost the global PARP inhibitors market in the next few years. Furthermore, the existing market players are deploying advanced techniques to come up with innovative methods for the development of technologically advanced treatments for cancer. This is likely to propel the demand for PARP inhibitors during the forecast period. However, frequent product recalls and stringent government regulations are expected to restrain the global market in the next few years.
Request for Analysis of COVID-19 Impact on PARP Inhibitors Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=71682
Increase in Incidence of Cancer Driving Global PARP Inhibitors Market
Cancer is the leading cause of death globally, after cardiovascular diseases. According to the World Health Organization (WHO), cancer accounts for 8.3 million deaths every year, with 70% new cancer cases expected to be reported in the next 20 years. Increase in the cancer-afflicted population is anticipated to be a key driver of the global PARP inhibitors market during the forecast period. According to a report by the Centers for Disease Control and Prevention (CDC) published in 2014, the number of cancer patients diagnosed in the U.S. reached approximately 21 million. The number is expected to reach 25.4 million by the end of 2024. Over 60% of the world’s new cancer cases occur in Asia, Africa, and South America. Nearly the same percentage of cancer deaths take place in these regions. Stomach, liver, lung, breast, and esophageal cancer are most prevalent worldwide.
Increase in Elderly Population Fueling Global PARP Inhibitors Market
Aging is associated with a large number of diseases and disorders. A majority of elderly people suffer from cancer. According to the Administration for Community Living, geriatric population (people aged 65 years or above) in the U.S. stood at 46.2 million in 2014. Thus, increase in elderly population is likely to drive the global PARP inhibitors market during the forecast period.
Pre Book PARP Inhibitors Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=71682<ype=S
Opportunities in Developing Regions
Developing regions such as Asia Pacific and Latin America are likely to be highly lucrative markets for PARP inhibitors in the near future. The market in these regions is projected to expand rapidly during the forecast period, owing to large population, increase in the number of hospitals, and rise in government investments in the advancement of health care facilities in these regions.
More Trending Reports by Transparency Market Research –
Home Blood Pressure Monitoring Devices Market: https://www.biospace.com/article/home-blood-pressure-monitoring-devices-market-increasing-in-awareness-regarding-advantages-of-home-bp-machines-and-launch-of-new-advanced-home-bp-monitors-to-drive-market/
Non-Invasive Prenatal Testing Market: https://www.prnewswire.com/news-releases/increased-maternal-age-of-large-populations-worldwide-generates-prodigious-sales-avenues-in-non-invasive-prenatal-testing-market-says-tmr-301285670.html
Contact
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com/
About Us
Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release China Market Analysis of PARP Inhibitors: Growth Opportunities here
News-ID: 2324278 • Views: …
More Releases from Transparency Market Research
Global Transfection Reagents and Equipment Market to Reach USD 2.4 Bn by 2035, D …
The global Transfection Reagents and Equipment Market is on a steady growth trajectory, supported by accelerating advancements in genetic research, increasing investments in cell and gene therapy, and the widespread adoption of cutting-edge gene-editing technologies such as CRISPR. Valued at US$ 1.2 Bn in 2024, the market is projected to reach US$ 2.4 Bn by 2035, expanding at a compound annual growth rate (CAGR) of 6.4% from 2025 to 2035.
Access…
SNP Genotyping and Analysis Market Expanding at 19.8% CAGR Through 2035 - By Sam …
The global SNP genotyping and analysis market was valued at US$ 27.4 billion in 2024 and is projected to reach US$ 199.2 billion by 2035, expanding at a robust compound annual growth rate (CAGR) of 19.8% during the forecast period from 2025 to 2035.
Explore pivotal insights and conclusions from our Report in this sample -
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=432
This exponential growth trajectory reflects the rising adoption of genomic technologies, increasing emphasis on personalized and…
3D Printing Materials Market Outlook 2035: Global Market to Surge from US 3.6 Bi …
The global 3D printing materials market is undergoing a transformative expansion, supported by rapid advancements in additive manufacturing technologies and accelerating adoption across industrial and commercial sectors. In 2024, the market was valued at US$ 3.6 Bn. Driven by strong demand from automotive, aerospace, healthcare, and consumer goods industries, the market is projected to reach an impressive US$ 41.1 Bn by 2035, registering a robust compound annual growth rate (CAGR)…
Small Modular Nuclear Reactors Market Outlook 2035: Advancing from US$ 5.9 Billi …
The global small modular nuclear reactors (SMRs) market is gaining strategic momentum as countries seek reliable, low-carbon, and scalable energy solutions to support decarbonization goals and long-term energy security. Valued at US$ 5.9 billion in 2024, the SMR market is projected to reach US$ 10.5 billion by 2035, expanding at a CAGR of 5.4% from 2025 to 2035. Unlike conventional large nuclear plants, SMRs offer flexible deployment, reduced capital risk,…
More Releases for PARP
PARP Inhibitors Market to Surpass USD 12 Billion by 2034,
Introduction
Cancer continues to be one of the most pressing healthcare challenges worldwide, and the demand for targeted, effective therapies has never been greater. Among the most promising innovations are Poly (ADP-ribose) polymerase (PARP) inhibitors, a class of drugs designed to exploit DNA repair weaknesses in cancer cells, particularly those with BRCA1/2 mutations. By preventing cancer cells from repairing DNA damage, PARP inhibitors lead to cell death, offering a new line…
PARP Inhibitor Biomarkers Market Size to Expand Lucratively by 2034
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global PARP Inhibitor Biomarkers Market - (By Product (Kits, Assays), By Services (BRCA 1 & 2 Testing, HRD Testing, HRR Testing, Others), By Application (Breast Cancer, Ovarian Cancer, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Global PARP Inhibitor Biomarkers Market is valued at US$ 879.8…
PARP Inhibitors Market Trends and Segments
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These…
PARP Inhibitors Market Dynamics, Segments, Size and Demand, 2017 - 2027
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These…
Global PARP Inhibitor Market: Size, Trends And Forecasts (2016-2020)
Scope of the Report
The report titled Global PARP Inhibitor Market: Size, Trends and Forecasts (2016-2020) provides an in-depth analysis of the global PARP inhibitor market with detailed analysis of market size on the basis of value along with the comprehensive examination of each of the segments of the market, namely, Lynparza, Niraparib, Rucaparib, Talazoparib and Veliparib.
The report analyses the global Lynparza market in detail along with the regional analysis as…
HT PARP in vivo Pharmacodynamic Assay II
Trevigen announces a validated assay, with higher sensitivity and pre-coated antibody plates to measure the effectiveness of PARP inhibitors in cell and tissue lysates for anticancer drug screening.
Pharmacodynamic (PD) assays have recently been developed and employed early in the drug screening process to assess the ability of potential drug candidates to affect molecular targets. These assays have the advantages of performing molecular proof-of-concept investigations at an early stage such as…
